Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label study of CAP-232 in metastatic kidney cancer
2006-004857-86Phase 2Terminated
- Sponsor
- CellCarta
- Start
- Nov 2006
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of TT-232 in kidney cancer, sponsored by CellCarta. Primary endpoints: Response rate, Adverse events and 4 more. Started Nov 2006; status: terminated.
02
Drugs
TT-232
03
Conditions
kidney cancer
Beyond the preview
Go deeper on 2006-004857-86.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-004857-86.